These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20220376)

  • 21. Raltegravir-based regimens are effective in HIV-1 group O-infected patients.
    Depatureaux A; Leoz M; Le Moal G; Pathé JP; Pavie J; Batisse D; Daneluzzi V; Genet P; Gerard L; Lascaux-Cametz AS; Lambolez T; Chennebault JM; Plantier JC
    J Acquir Immune Defic Syndr; 2012 Sep; 61(1):e1-3. PubMed ID: 22918125
    [No Abstract]   [Full Text] [Related]  

  • 22. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapies. Confronting the limits of success.
    Cohen J
    Science; 2002 Jun; 296(5577):2320-4. PubMed ID: 12089422
    [No Abstract]   [Full Text] [Related]  

  • 25. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy.
    Zhang S; van Sighem A; Kesselring A; Gras L; Smit C; Prins JM; Kauffmann R; Richter C; de Wolf F; Reiss P
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):265-72. PubMed ID: 22531756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.
    Tuboi SH; Brinkhof MW; Egger M; Stone RA; Braitstein P; Nash D; Sprinz E; Dabis F; Harrison LH; Schechter M
    J Acquir Immune Defic Syndr; 2007 May; 45(1):52-9. PubMed ID: 17460471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia.
    Borkowsky W; Yogev R; Muresan P; McFarland E; Frenkel L; Fenton T; Capparelli E; Moye J; Harding P; Ellis N; Heckman B; Kraimer J
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):401-11. PubMed ID: 18327977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term clinical and immunological outcome in patients with HIV-infection and virologic failure].
    Julián Moreno-Cuerda V; Morales-Conejo M; Tamargo L; Rubio R
    Med Clin (Barc); 2005 May; 124(19):755. PubMed ID: 15919039
    [No Abstract]   [Full Text] [Related]  

  • 30. Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.
    Joya C; Won SH; Schofield C; Lalani T; Maves RC; Kronmann K; Deiss R; Okulicz J; Agan BK; Ganesan A
    Clin Infect Dis; 2019 Nov; 69(12):2145-2152. PubMed ID: 30785191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
    Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
    AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-specific immunity during structured antiviral drug treatment interruption.
    Moss RB; Brandt C; Giermakowska WK; Savary JR; Theofan G; Zanetti M; Carlo DJ; Wallace MR
    Vaccine; 2003 Mar; 21(11-12):1066-71. PubMed ID: 12559781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario.
    Tumbarello M; Rabagliati R; De Gaetano Donati K; Bertagnolio S; Tamburrini E; Tacconelli E; Cauda R
    AIDS; 2003 Jan; 17(1):128-31. PubMed ID: 12478081
    [No Abstract]   [Full Text] [Related]  

  • 37. Biphasic decline of CD4 cell count during scheduled treatment interruptions.
    Fagard C; Bandelier CY; Ananworanich J; Le Braz M; Günthard H; Perneger T; García F; Hirschel B;
    AIDS; 2005 Mar; 19(4):439-41. PubMed ID: 15750398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
    Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC
    AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course.
    Tenorio AR; Smith KY; Kuritzkes DR; Sha BE; Donoval B; Young R; Jennings C; Bremer J; Shott S; Landay A; Kessler HA
    J Acquir Immune Defic Syndr; 2003 Dec; 34(5):491-6. PubMed ID: 14657759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial suboptimal CD4 reconstitution with antiretroviral therapy despite full viral suppression in a cohort of HIV-infected patients in Senegal.
    Batista G; Buvé A; Ngom Gueye NF; Manga NM; Diop MN; Ndiaye K; Thiam A; Ly F; Diallo A; Ndour CT; Seydi M
    Med Mal Infect; 2015 Jun; 45(6):199-206. PubMed ID: 25907261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.